About: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.09 (+1.64%)
BCTX NASDAQ Briacell Therapeutics Corp
Briacell Therapeutics Corp share price
BCTX price activity
Last Price
$3.090
Change (24hr)
0.05 USD (1.64%)
Volume
60.03K
Volume (4w avg)
-
Open
$3.07
Day Range
$3.05 - $3.20
Previous Close
$3.04
Last Trade
02 Nov, 9:00 pm GMT+0
Delayed
02 Nov, 9:00 pm GMT+0
BCTX price performance
Delayed
02 Nov, 9:00 pm GMT+0
BCTX Market Signals